Cynata Therapeutics Limited (ASX: CYP) - Share Price
- Current share price for CYP : $0.260
Cynata Therapeutics Limited (CYP), an ASX-listed company, is a Company that is engaged in development and commercialisation of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus.
CYP General Information +
| ASX Code | CYP |
| Website | http://www.cynata.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 63 |
| CYP Share Price | $0.260 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.260 |
| CYP Share Price Movement | - ( No change ) |
Prices as at 16:40, 12 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Cynata Therapeutics Limited (CYP) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Cynata Therapeutics Limited (CYP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Cynata Therapeutics Limited (CYP) price-sensitive announcements
CYP - Trading Halt
Cynata Therapeutics Limited has requested a trading halt for its securities, effective 12
Cynata Therapeutics Limited (CYP)
12 Jun 2026 | 9:46 AM
12 Jun 2026 | 9:46 AM
CYP - EU Positive Opinion on CYP-001 Paediatric Investigation Plan
Cynata Therapeutics Limited has received a Positive Opinion from the European Medicines Ag
Cynata Therapeutics Limited (CYP)
3 Jun 2026 | 8:48 AM
3 Jun 2026 | 8:48 AM
CYP - Cynata Secures Commitments for $1.5m Placement
Cynata Therapeutics Limited has announced it has secured commitments to raise A$1.5 millio
Cynata Therapeutics Limited (CYP)
4 May 2026 | 9:05 AM
4 May 2026 | 9:05 AM
CYP - March 2026 Quarterly Activity Report & Appendix 4C
Cynata Therapeutics Limited (ASX: CYP) released its March 2026 Quarterly Activity Report,
Cynata Therapeutics Limited (CYP)
30 Apr 2026 | 10:00 AM
30 Apr 2026 | 10:00 AM
Cynata Therapeutics Limited (CYP) Recent ASX Announcements
CYP Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$9.39 | -$4.60 | -15.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$9.74 | -$5.40 | -44.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$14.28 | -$9.80 | 159.00% | 0.00 | 0.00 | 0.00% | 0.0% |
CYP Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $51,354M | 0.1108 | -0.1365 | 0.0438 | 11.4983 | 13.3154 | 12.7567 | 4.16% | 3.34% | 3.47% |
| Clinuvel Pharmaceuticals Limited (CUV) | $446M | 0.0287 | 0.0233 | 0.0942 | 12.3259 | 12.0457 | 11.0088 | 0.56% | 0.82% | 1.32% |
| Cynata Therapeutics Limited (CYP) | $63M | -0.1550 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,550M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,571M | -1.3893 | 0.0000 | -0.1316 | 0.0000 | 253.1955 | 291.5584 | 0.00% | 0.00% | 0.00% |
CYP Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 9.81 | 0.00 |
| Market | 0.32 | 12.90 | 1.16 | 0.66 |
| Sector | 0.40 | 27.30 | 2.56 | 2.10 |
CYP Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Kilian Kelly | Chief Executive Officer, Managing Director | 1 Jul 2023 |
| Mr Peter Webse | Company Secretary | 1 Jan 0001 |
| Dr Paul K Wotton | Non-Executive Director | 8 Jun 2016 |
| Ms Janine Rolfe | Non-Executive Director | 1 Sep 2022 |
| Dr Darryl Maher | Non-Executive Director | 16 Jun 2020 |
| Dr Geoffrey Edward Duncan Brooke | Non-Executive Director, Non-Executive Chairman | 20 May 2019 |
Cynata Therapeutics Limited (CYP) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 20 Feb 2025 | WOTTON, Paul | Exercise | Options | 69,767 | $0.300 | $20,930.100 |
| 20 Feb 2025 | WOTTON, Paul | Buy | Direct Shares | 69,767 | $0.300 | $20,930.100 |
| 23 Jan 2025 | BROOKE, Geoffrey | Issued | Indirect Shares | 55,555 | $0.180 | $9,999.900 |
See all changes in directors' interest & trades for Cynata Therapeutics Limited (CYP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CYP Management
| Name | Position |
|---|---|
| Mathias Kroll | Chief Business Officer |
| Jolanta Airey | Chief Medical Officer |
CYP Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cynata Therapeutics Limited (CYP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 23,588,040 (9.93%) | Phillip Asset Management Ltd |
| 20,967,806 (8.83%) | FIL Limited and the entities |
CYP Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 09 October 2026 | Report (Annual) |
| 27 August 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
